PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo

Prostate

Volumn 42, Issue 3, 2000, Pages 163-171

  Kubota, Tetsuya ^a   Hisatake, Junichi ^a   Hisatake, Yasuko ^a   Said, Jonathan W ^a   Chen, Sophie S ^b   Holden, Stuart ^a   Taguchi, Hirokuni ^c   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Herb; In vivo model; PC SPES; Prostate cancer

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; GANODERMA LUCIDUM EXTRACT; HERBACEOUS AGENT; SABAL EXTRACT; SCUTELLARIAE RADIX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; GINSENG; GLYCYRRHIZA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CADHERINS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASES; DRUGS, CHINESE HERBAL; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TELOMERASE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0034651570     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000215)42:3<163::AID-PROS1>3.0.CO;2-W     Document Type: Article

References (37)

1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804-818.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. Niles RM. Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp Med Biol 1995;375:1-15.
4. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989;320: 980-991.
5. Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997;89:182-185.
6. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352.
7. Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 1998;16:6-12.
8. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993;328: 246-252.
9. Hsieh T, Chen SS, Wang X, Wu JM. Reguĺation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochern Mol Biol Int 1997;42:535-544.
10. Halicka HD, Ardelt B, Juan G, Mittelman A, Chen S, Traganos F, Darzynkiewicz Z. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. Int J Oncol 1997;11:437-448.
11. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, Zhu BT, Spaulding H, Goodin S, Toledano MB, Hait WN, Gallo MA. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339:785-791.
12. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996;88:2201-2209.
13. kip1 and E-cadherin. J Mol Endocrinol 1997;19:15-27.
14. 3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 1998;58:3370-3375.
15. 3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Res 1997;57:4545-4550.
16. 3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol 1998;13:421-428.
17. Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, Rübben H. E-cadherin: a marker for differentiation and invasiveness in prostate cancer. Urol Res 1993;21:359-362.
18. Carrol AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three prostate cancer cell lines. Prostate 1993;23: 123-134.
19. Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Debruyne FM, Schalken JA. p16 mutations/deletions are not frequent events in prostate cancer. Br J Cancer 1996;74:120-122.
20. 3 analog. Endocrinology 1998; 139:1972-1980.
21. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 1997;66:413-425.
22. de Vos S, Dawson MI, Holden S, Le T, Wang A, Cho SK, Chen D, Koeffler HP. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate 1997;32:115-121.
23. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366: 701-704.
24. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993;75:805-816.
25. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular anti-mitogenic signals. Cell 1994;78:59-66.
26. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
27. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, potent mediator of p53 tumor suppression. Cell 1993;75:817-825.
28. cip1/waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998;18:629-643.
29. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
30. Ozen M, Imam SA, Datar RH, Multani AS, Narayanan R, Chung LW, von Eschenbach AC, Pathak S. Telomeric DNA: marker for human prostate cancer development? Prostate 1998;36:264-271.
31. Robertson CN, Robertson KM, Padilla GM, O'Brien ET, Cook JM, Kim C. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996; 88:908-917.
32. Small EJ. PC-SPES in prostate cancer [letter]. N Engl J Med 1999;340:566-567.
33. de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. Effects of a phytotherapeutic agent, PC-SPES in prostate cancer: a preliminary investigation on human cell lines and patients. Br J Urol 1999; in press.
34. Mittelman A, Tiwari RK, Chen S, Geliebter J. In: Preclinical analysis of the in vivo and in vitro effects of PC-SPES on rat prostate cancer cells. Annual Meeting of the ASCO 1999; abstract #150843.
35. Hsieh T, Ng C, Chang C, Chen SS, Mittleman A, Wu JM. Induction of apoptosis and down-regulation of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol 1998;13:1192-1202.
36. Tiwari RK, Geliebter J, Garikapaty VPS, Yedavelli SPK, Chen S, Mittelman A. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 1999;14:713-719.
37. Geliebter J, Tiwari R, Wu JM. PC-SPES in prostate cancer [letter]. N Engl J Med 1999;340:567.